What Happened?
Lexington, MA-based Cyteir Promoted David Gaiero as Chief Financial Officer
About the Company
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
About the Person
David Gaiero is Chief Financial Officer at Cyteir. Previously, David held various senior HR leadership roles in the industry.
Info Source
News
Short Profile